インメッド・ファーマシューティカルズ
InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q4 | -1.43 | $2.1B | -$3M |
| 2026 Q3 | -0.73 | $0 | -$2M |
| 2025 Q2 | -0.71 | $1M | -$3M |
| 2025 Q1 | -0.61 | $1M | -$2M |
| 2025 Q4 | -1.22 | $2M | -$2M |
| 2025 Q3 | -1.94 | $1M | -$2M |
| 2024 Q2 |
| -3.64 |
| $1M |
| -$3M |
| 2024 Q1 | -2.71 | $1M | -$2M |